Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Rare Disease Genome Editing Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The market for genome editing in rare diseases has undergone rapid expansion in recent years, with its value projected to increase from $1.29 billion in 2025 to $1.51 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.8%. This historic growth was driven by progress in gene editing tools, a greater number of rare genetic mutations being identified, increased funding allocated to genomic research, encouraging outcomes from early gene therapy clinical trials, and a rise in academic research programs.
The market for rare disease genome editing is set to experience substantial expansion in the near future, projected to reach a valuation of $2.88 billion by 2030 with a compound annual growth rate of 17.5%. This upward trajectory in the forecast period is driven by higher levels of investment directed toward curative therapies for rare conditions, a greater embrace of precision medicine techniques, a broadening scope of clinical trials involving genome editing, enhanced regulatory frameworks supporting orphan drug development, and strengthened partnerships between biotechnology firms and healthcare organizations. Key emerging trends shaping this period include a growing reliance on crispr-based treatments, an intensified emphasis on editing genes associated with monogenic disorders, a heightened application of customized genome editing strategies, the development of more sophisticated editing platforms, and a deeper integration of genomic data analysis tools.
Download A Free Sample Report For Comprehensive Market Insights:
Rare Disease Genome Editing Market Growth Drivers: What Factors Are Accelerating Expansion?
The rare disease genome editing market is anticipated to expand due to a growing emphasis on precision medicine. This approach to healthcare customizes treatments based on an individual’s genetic profile, environment, and lifestyle to enhance accuracy and effectiveness. Its rising prominence stems from progress in genomic sequencing and biomarker discovery, which facilitate precise diagnosis and targeted therapies. The genome editing market contributes to this field by enabling exact correction of genetic defects, thereby tailoring interventions to each patient. This method transforms healthcare by tackling the fundamental causes of uncommon disorders, leading to superior patient outcomes and less dependence on symptom-focused care. A case in point is Novotech, an Australian biotech firm, which reported in March 2024 that 43% of the 217 FDA-endorsed oncology therapies in 2023 were precision oncology, with 78 utilizing DNA or NGS-detectable biomarkers. Consequently, the heightened focus on precision medicine is fueling growth in the rare disease genome editing market.
Rare Disease Genome Editing Market Segmentation And Category Breakdown
The rare disease genome editing market covered in this report is segmented –
1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies
2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders
3) By Application: Therapeutics, Research
4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals
Subsegments:
1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing
2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases
3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)
4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases
Rare Disease Genome Editing Market Trends: What Is Shaping Future Industry Growth?
Key players in the rare disease genome editing market are concentrating their efforts on creating advanced therapeutic platforms, including CRISPR-based gene editing systems, with the goal of improving treatment accuracy, boosting clinical results, and tackling genetic diseases that were once considered incurable. These CRISPR-based systems represent innovative tools capable of making precise alterations to the genome, enabling the repair of genetic abnormalities or the insertion of therapeutic genes within human cells. As an example, in December 2023, Vertex Pharmaceuticals Inc., a biopharmaceutical firm from the United States, joined forces with CRISPR Therapeutics Inc., an American biotechnology research company, and secured conditional marketing approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This treatment is intended for individuals aged 12 and older who suffer from sickle cell disease (SCD) with recurring vaso-occlusive crises, or transfusion-dependent beta thalassemia (TDT). Casgevy operates by modifying a patient’s hematopoietic stem cells to restore fetal hemoglobin production, thereby lessening or eradicating disease manifestations and offering a possible functional cure for these conditions.
Rare Disease Genome Editing Market Competitive Analysis Of Major Industry Participants
Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc
Access The Complete Rare Disease Genome Editing Market Report:
Rare Disease Genome Editing Market Regional Analysis And Leading Geography
North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model